Pfizer (NYSE:PFE) will reportedly acquire Seagen (NASDAQ:SGEN) for $43 billion in total enterprise value for $229 per share in cash. Seagen’s risk-adjusted revenue contribution is expected to exceed $10 billion in 2030. Pfizer expects to finance the transaction primarily through a new borrowing of $31 billion of long-term debt, with the remainder coming from short-term financing and cash on hand.